DOCSLIB.ORG

In Ammatory and Infectious Upper Respiratory Diseases Associate With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Ammatory and Infectious Upper Respiratory Diseases Associate With Inammatory and infectious upper respiratory diseases associate with 59 genomic loci that link to type 2 inammation genes Elmo Saarentaus University of Helsinki https://orcid.org/0000-0002-8475-7187 Juha Karjalainen The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA Joel Rämö Helsinki Institute of Life Science Tuomo Kiiskinen Institute for Molecular Medicine Finland https://orcid.org/0000-0002-6306-8227 Aki Havulinna Helsinki Institute of Life Science Juha Mehtonen Helsinki Institute of Life Science Heidi Hautakangas Helsinki Institute of Life Science Sanni Ruotsalainen Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki https://orcid.org/0000-0002-1631-4069 Sanna Salmi Helsinki Institute of Life Science Matti Pirinen University of Helsinki https://orcid.org/0000-0002-1664-1350 Mitja Kurki Helsinki Institute of Life Science Samuli Ripatti Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki Mark Daly Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki Tuula Palotie Helsinki Institute of Life Science Antti Mäkitie Helsinki Institute of Life Science Aarno Palotie ( aarno.palotie@mm. ) Helsinki Institute of Life Science Genetics Article Keywords: upper respiratory diseases, autoimmune disease, inammation genes Posted Date: July 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-654053/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License 1 Inflammatory and infectious upper respiratory diseases associate with 59 2 genomic loci that link to type 2 inflammation genes 3 Authors: Elmo C. Saarentaus1, Juha Karjalainen1,2,3, Joel T. Rämö1, Tuomo Kiiskinen1,4, Aki S. 4 Havulinna1,4, Juha Mehtonen1, Heidi Hautakangas1, Sanni Ruotsalainen1, FINNGEN, Sanna 5 Toppila-Salmi5, Matti Pirinen1,6,7, Mitja Kurki1,2,3, Samuli Ripatti1,2,3, Mark Daly1,2,3, Tuula 6 Palotie8,9, Antti Mäkitie10, Aarno Palotie1,2,11* 7 Affiliations: 8 1Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, 9 Finland. 10 2Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, 11 Massachusetts, USA. 12 3Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, 13 Massachusetts, USA. 14 4Finnish Institute for Health and Welfare, Helsinki, Finland. 15 5Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, 16 Finland 17 6Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland 18 7Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland 19 8Orthodontics, Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, 20 University of Helsinki, Helsinki, Finland; 21 9Oral and Maxillofacial Diseases, Helsinki University Hospital, Helsinki, Finland 22 10Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and 23 Helsinki University Hospital, Helsinki, Finland. 24 11Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology 25 and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 26 *Corresponding author. Email: [email protected] 27 0 28 One Sentence Summary: Inflammatory upper respiratory diseases share genetic risk loci and 29 correlate genetically with each other and with diseases of the immune system 30 Abstract: 31 Inflammatory and infectious upper respiratory diseases (IURDs; ICD-10: J30-J39), such as 32 diseases of sinonasal tract, pharynx and larynx, are growing health problems yet their genomic 33 similarity is not known. We analyzed genome-wide association to eight IURDs (61,195 cases) 34 among 260,405 FinnGen participants, meta-analyzing diseases in four groups based on an 35 underlying genetic correlation structure. We aimed to understand which genetic loci contribute to 36 susceptibility to IURDs in general and its subtypes. We detected 59 independent genome-wide 37 significant (GWS) loci, distinguishing impact on sinonasal or pharyngeal diseases, or both. Fine- 38 mapping implicated non-synonymous variants in 16 genes, including 10 linked to immune- 39 related diseases. Phenome-wide analysis implicated asthma and atopic dermatitis at sinonasal 40 disease loci and inflammatory bowel diseases, and other immune-mediated disorders at 41 pharyngeal disease loci. IURDs also genetically correlated with autoimmune diseases such as 42 rheumatoid arthritis, autoimmune hypothyroidism, and psoriasis. Finally, we associated separate 43 gene pathways in sinonasal and pharyngeal diseases that both contribute to type 2 immunological 44 reaction. We show shared heritability among IURDs that extends to several immune-mediated 45 diseases with diverse mechanisms, such as type 2 high inflammation. 1 46 Main Text: 47 INTRODUCTION 48 Inflammatory and infectious upper respiratory diseases (IURD) affect the sinonasal tract, 49 pharynx, and larynx, and include diseases such as chronic tonsillitis, allergic rhinitis, and chronic 50 rhinosinusitis. They lead to increased morbidity1,2 and costs3, and to the highest public health 51 burden in the world4 by serving as the main route of infection to the body, and by their 52 connection to non-communicable diseases, such as asthma5-7, autoimmune diseases8,9, 53 cardiovascular diseases10 and obesity11. Genetic predisposition12-15 together with environmental 54 megatrends such as the COVID-19 pandemic16-18, Western lifestyle19, urbanization20,21, global 55 warming22 and dysbiosis23,24 influence the burden of IURDs. IURDs often co-exist25-28, and they 56 have shown overlapping mechanisms5,6,29,30. Understanding the genetic (dis)similarities behind 57 IURDs can remarkably improve preventive actions and therapies, and reduce the burden of 58 IURDs and related diseases2,31. 59 IURDs are characterized by an etiology related to recurrent infections and dysbiosis20,21,24 60 leading to chronic and treatment-resistant diseases32 with acute and even life-threatening 61 exacerbations. IURDs involve inflammation in the nasal cavity, such as vasomotor and allergic 62 rhinitis (VAR), both characterized by hyperresponsiveness to stimuli33; non-specific chronic 63 rhinitis, nasopharyngitis and pharyngitis (CRNP) and nasal septal deviation (NSD); and in the 64 adjoining paranasal sinuses, such as chronic rhinosinusitis (CRS) with or without nasal polyps 65 (NP)6. Allergic rhinitis (AR) is a part of an allergic disease entity involving allergic asthma, 66 atopic dermatitis, allergic conjunctivitis and food allergy27,34,35. IURDs also encompass other 2 67 diseases of the pharynx such as chronic laryngitis and laryngotracheitis (CLT), chronic diseases 68 of tonsils and adenoids (CDTA), and peritonsillar abscess (PA). Previous genetic studies of 69 IURDs and related immune responses have largely focused on rare variants36 and the HLA 70 region37,38. IURD-related GWAS have been reported of CRS and NP39, tonsillectomy and 71 childhood ear infections40,41, cold sores, mononucleosis, strep throat, pneumonia and 72 myringotomy40, hay fever39-42, and of infective diseases caused by specific airway-related 73 microbes such as pneumococcus43 and staphylococcus aureus44. However, no prior research has 74 analyzed shared genetic contributions of IURDs. 75 The FinnGen study is a large biobank study including both genetic and lifelong health record 76 data from all participants, thus allowing the investigation of potentially shared and distinct 77 genetic landscape associated to IURDs. This provides an opportunity both for GWASs as well as 78 for cross-disease analyses to better understand potential shared genetic contributors. We aimed to 79 study genetic predispositions to recurrent, chronic and complicated IURDs. We hypothesized 80 that, on one hand, shared genetic variants contribute to IURD susceptibility in general, and some 81 variants contribute more to distinct IURD phenotypes. To test this hypothesis, we analyzed 82 genome-wide association of IURD cases in the FinnGen study (release 6/Aug 2020), a nation- 83 wide collection of genotyped samples from Finnish individuals. Our study sample included 84 260,405 individuals of all ages, where we focused on cases of specialist-diagnosed IURDs (n = 85 61,197), including their more specific diagnosis. We tested the genetic associations across 86 IURDs to highlight shared and distinct genetic contributions among IURDs. Finally, we 87 compared the genome-wide association of IURDs and phenotypes to other anatomically related 3 88 and systemic immunological disorders (such as chronic periodontitis) linked with the same 89 genetic loci. 4 90 RESULTS 91 Genome-wide association of inflammatory and infectious upper respiratory diseases 92 We performed genome-wide association of all IURD cases (n = 61,197, ranging from 2,623 to 93 29,135 per phenotype) in FinnGen. We genotyped and imputed 16,355,289 single-nucleotide 94 genetic variants in 260,405 Finnish individuals of all ages. We used a logistic mixed model with 95 the SAIGE software45 (see Methods) to detect genome-wide association between 61,197 cases of 96 IURDs (Table 1, Supplementary Figure 1) and 199,208 controls, and set as covariates age, 97 genetic sex, principal components (PCs) 1–10, and genotyping batch. This resulted in 698 98 genome-wide significant (GWS, p<5e-8) SNPs in 20 loci (Table 2). Fine-mapping using the 99 SuSiE software46 on the 19 non-HLA loci identified 21 independent credible
Load more

Recommended publications
  • The Path to New Therapies for Schizophrenia and Bipolar Illness
    THE JOURNAL • PERSPECTIVE • www.fasebj.org The Path to New Therapies for Schizophrenia and Bipolar Illness Edward M. Scolnick1 Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA ABSTRACT: Schizophrenia and bipolar illness are two of the most serious forms of mental illness. Until relatively recently, almost nothing was known about the molecular pathogenesis of either illness. The single largest risk factor that predisposes people to schizophrenia or bipolar illness is genetic risk. Heritability is high, and the incidence is significantly higher in identical twins than in nonidentical twins. Despite decades of work aimed at identifying the genes involved in these two illnesses, virtually no progress had been made until the past decade. With the knowledge and technologies that have been gained from the Human Genome Project, it has been possible to begin to understand the underlying genetics and to use the new information to begin the effort to discover new and better medicines to treat these illnesses. This article will describe the past decade of work toward this goal and articulate both the promise that now exists and what is still needed to bring dramatic and tangible change to patients.—Scolnick, E. M. The path to new therapies for schizophrenia and bipolar illness. FASEB J. 31, 1254–1259 (2017). www.fasebj.org KEY WORDS: genetics • pharmacology • progress In the fall of 2004, I became an associate member of the bipolar illness for many years. Virtually no reproducible Broad Institute, founded on the principle of collaboration results had been achieved. The Broad Institute had a su- among scientists at the Massachusetts Institute of Tech- perb group of scientific experts in human genetics, a field nology, Harvard, and Harvard-affiliated hospitals.
    [Show full text]
  • Aarhus University Honorary Doctorate Seminar Friday 13 September 2019 at 10.00 – 11.15
    Department of Biomedicine Center for Genomics Personalized Medicine and Personalized Medicine Aarhus University Honorary Doctorate Seminar Friday 13 September 2019 at 10.00 – 11.15 Professor Mark Daly, Institute for Molecular Medicine Finland. Analytic and Translational Genetics Unit, USA. Broad Institute of Harvard and MIT, USA. Talk: Global partnerships: From Psychiatric Genetics to FinnGen and opportunities in discovery, prevention and personalized medicine. Venue: Eduard Biermann Auditory, The Lakeside Theatres, Aarhus University, Bartholins Allé 3, 8000 Aarhus C. Programme 10.00 – 10.05 Welcome by Anders Børglum 10.05 – 10.50 AU Honorary Doctorate lecture by Mark Daly 10.50 – 11.15 Open discussion Biosketch: Mark Daly, PhD, was appointed Director of the Institute for Molecular Medicine Finland (FIMM) in February 2018. He retains also his affiliations in Boston at the Harvard Medical School, Massachusetts General Hospital and as an institute member of the Broad Institute and co-director of the Program in Medical and Population Genetics. Daly received his B.S. in physics from the Massachusetts Institute of Technology and his Ph.D. in human genetics from Leiden University, Netherlands. He received the Curt Stern Award from the American Society of Human Genetics in 2014 and is a member of the National Academy of Medicine. Department of Biomedicine Center for Genomics Personalized Medicine and Personalized Medicine His research primarily focuses on the development and application of statistical methods for the discovery and interpretation of genetic variation responsible for complex human disease. In addition to foundational work in human genetics methodology, his lab has made major contributions to gene discovery in inflammatory bowel disease, autism and schizophrenia - primarily through catalyzing global collaborative research efforts which he continues to help lead.
    [Show full text]
  • Implementing Physician Education Programs
    Informatic Imperatives for Sequencing in Large-Scale Studies Daniel MacArthur Analytic and Translational Genetics Unit, Massachusetts General Hospital Broad Institute of Harvard and MIT Harvard Medical School 1000 Genomes Project Consortium Acknowledgments • Shane McCarthy (Sanger) • Mark DePristo, Ryan Poplin and Khalid Shakir (Broad) • Mark Daly and David Altshuler (MGH/Broad) • 1000 Genomes Analysis Group A plausible near-future scenario • we have exome sequence and complex phenotype data available for 100,000 individuals from multiple sources • one petabyte of raw data • goals: – create accurate, consistent variant calls across all samples – harmonized, cleaned phenotype data – data are not just accessible but usable by researchers from the wider community Key challenges • Logistics: moving, storing and crunching large data-sets • Harmonization: integrating and cleaning data from multiple sources • Analysis: extracting useful information from massive, structured data-sets • Access: making data available and usable for many different audiences Logistics: data management • 100,000 exomes 1 petabyte raw data – with 10 Gbit connection, 1-6 months – may be faster to use truck full of hard drives • data storage is not free: – expect ~$1M/year for 100K exomes • ~10x greater for WGS; less with compression • but community now has extensive experience in handling large sequence data: logistical problems are soluble Logistics: QC and meta-data • sample-tracking: – genetic data: easy ID of duplicates, sample swaps, pedigree and population errors
    [Show full text]
  • Ryan L. Collins
    RYAN LEWIS COLLINS Ph.D. Candidate, Bioinformatics and Integrative Genomics Ph.D. Program, Harvard Medical School 185 Cambridge St., Floor 5 Boston, MA, 02114 NSF Graduate Research Fellow, Talkowski Laboratory, Massachusetts General Hospital (603) 290-2200 Team Leader, Population Genetics & Genome Biology, Broad-SV Group, Broad Institute of MIT and Harvard www.RyanLCollins.com [email protected] § Professional status: third-year Ph.D. § Career objective: to advance knowledge § Scientific interests: structural variation, candidate at Harvard Medical School of the structure-function dynamics in the chromatin, genome topology, sequencing studying human genome structure & human genome, and their implications for technologies, interpretation of genetic function in the lab of Dr. Michael development, disease, population genetics, variation, gene regulation & regulatory Talkowski at Massachusetts General and precision medicine, ideally by leading elements, statistics, predictive modeling, Hospital and The Broad Institute. an independent research group. bioinformatics, and clinical genetics. EDUCATION DEGREES Ph.D. Harvard Medical School, Boston, MA, USA 2016-Present Division of Medical Sciences: Bioinformatics and Integrative Genomics Thesis Title The properties of natural selection on structural variation in the human genome Advisor Michael E. Talkowski, Ph.D. Dissertation Committee Shamil Sunyaev, Ph.D.; Mark Daly, Ph.D.; James Gusella, Ph.D.; Marcin Imielinski, M.D., Ph.D. A.B. Dartmouth College, Hanover, NH, USA 2009-2013 Department
    [Show full text]
  • The Genome Analysis Toolkit: a Mapreduce Framework for Analyzing Next-Generation DNA Sequencing Data
    The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation McKenna, A., M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, et al. “The Genome Analysis Toolkit: A MapReduce Framework for Analyzing Next-Generation DNA Sequencing Data.” Genome Research 20, no. 9 (September 1, 2010): 1297–1303. As Published http://dx.doi.org/10.1101/gr.107524.110 Publisher Cold Spring Harbor Laboratory Press Version Final published version Citable link http://hdl.handle.net/1721.1/88421 Terms of Use Creative Commons Attribution-Noncommerical Detailed Terms http://creativecommons.org/licenses/by-nc/3.0/ Downloaded from genome.cshlp.org on June 16, 2014 - Published by Cold Spring Harbor Laboratory Press The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data Aaron McKenna, Matthew Hanna, Eric Banks, et al. Genome Res. 2010 20: 1297-1303 originally published online July 19, 2010 Access the most recent version at doi:10.1101/gr.107524.110 Supplemental http://genome.cshlp.org/content/suppl/2010/07/14/gr.107524.110.DC1.html Material References This article cites 26 articles, 13 of which can be accessed free at: http://genome.cshlp.org/content/20/9/1297.full.html#ref-list-1 Creative This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the Commons first six months after the full-issue publication date (see License http://genome.cshlp.org/site/misc/terms.xhtml).
    [Show full text]
  • Genome-Wide Association Study Reveals First Locus for Anorexia Nervosa and Metabolic Correlations
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Am J Psychiatry Manuscript Author . Author Manuscript Author manuscript; available in PMC 2018 September 01. Published in final edited form as: Am J Psychiatry. 2017 September 01; 174(9): 850–858. doi:10.1176/appi.ajp.2017.16121402. Genome-Wide Association Study Reveals First Locus for Anorexia Nervosa and Metabolic Correlations Laramie Duncan, PhD, Zeynep Yilmaz, PhD, Raymond Walters, PhD, Jackie Goldstein, PhD, Verneri Anttila, PhD, Brendan Bulik-Sullivan, PhD, Stephan Ripke, MD, PhD, Eating Disorders Working Group of the Psychiatric Genomics Consortium, Laura Thornton, PhD, Anke Hinney, PhD, Mark Daly, PhD, Patrick Sullivan, MD, FRANZCP, Eleftheria Zeggini, PhD, Gerome Breen, PhD, and Cynthia Bulik, PhD Abstract Objective—To conduct a genome-wide association study (GWAS) of anorexia nervosa and to calculate genetic correlations with a series of psychiatric, educational, and metabolic phenotypes. Method—Following uniform quality control and imputation using the 1000 Genomes Project (phase 3) in 12 case-control cohorts comprising 3,495 anorexia nervosa cases and 10,982 controls, we performed standard association analysis followed by a meta-analysis across cohorts. Linkage disequilibrium score regression (LDSC) was used to calculate genome-wide common variant heritability [ , partitioned heritability, and genetic correlations (rg)] between anorexia nervosa and other phenotypes. Results—Results were obtained for 10,641,224 single nucleotide polymorphisms (SNPs) and insertion-deletion variants with minor allele frequency > 1% and imputation quality scores > 0.6. The of anorexia nervosa was 0.20 (SE=0.02), suggesting that a substantial fraction of the twin-based heritability arises from common genetic variation.
    [Show full text]
  • Studying Genetic Variation II: Computational Techniques
    Studying Genetic Variation II: Computational Techniques Jim Mullikin, PhD Genome Technology Branch NHGRI Some points from the previous two lectures • Genetic maps, markers and linkage analysis by Elaine Ostrander – Genome wide scans for Mendelian inherited disease, microsatellites are still an effective marker to use • Genetic Variation I: Laboratory Techniques by Karen Mohlke – Types of polymorphisms and genotyping methods, focusing primarily on SNP genotyping 1 Overview of Topics • Genome variation origins • Types of polymorphisms • SNP discovery methods • Access to genetic variation data • How to find SNPs in a region of interest • Haplotype Map project Overview of Topics • Genome variation origins • Types of polymorphisms • SNP discovery methods • Access to genetic variation data • How to find SNPs in a region of interest • Haplotype Map project 2 Discovery methods • The primary method for discovering polymorphisms is by sequencing DNA and comparing the sequences. Trace Archive Search query: trace_name='S213P602260RC9.T0' OR trace_name='50766946' 3 Mining SNPs from sequence • EST mining • Clone overlap • The SNP Consortium (TSC) • Targeted resequencing • Haplotype Map Project (HapMap) • Chip based sequencing arrays Expressed Sequence Tag Mining • These sequences are primarily associated with coding regions of genes. • By clustering these sequences, selected differences are identified as SNPs. • There are over 100,000 SNPs in dbSNP from a variety of species detected from clustered ESTs. • The following example is from the CGAP SNP project (see refs). 4 Clone Overlap • The human genome was sequenced from BAC clones (containing about 150kb of sequence each). • These overlapped to various levels, and within the overlap regions, high quality base differences indicated the position and alleles of SNPs.
    [Show full text]
  • Curriculum Vitae: Ryan L. Collins
    RYAN LEWIS COLLINS Ph.D. Candidate, Bioinformatics and Integrative Genomics Ph.D. Program, Harvard Medical School 185 Cambridge St., Floor 5 Boston, MA, 02114 NSF Graduate Research Fellow, Talkowski Laboratory, Massachusetts General Hospital (603) 290-2200 Team Leader, Population Genetics & Genome Biology, Broad-SV Group, Broad Institute of MIT and Harvard www.RyanLCollins.com [email protected] § Professional status: fourth-year Ph.D. § Career objective: to advance knowledge § Scientific interests: structural variation, candidate at Harvard Medical School of the structure-function dynamics in the chromatin, genome topology, sequencing studying human genome structure & human genome and their implications for technologies, interpretation of genetic function in the lab of Dr. Michael development, disease, population genetics, variation, gene regulation & regulatory Talkowski at Massachusetts General and precision medicine, ideally by leading elements, statistics, predictive modeling, Hospital and The Broad Institute. an independent research group. bioinformatics, and medical genetics. EDUCATION DEGREES Ph.D. Harvard University, Cambridge, MA, USA 2016-Present Division of Medical Sciences: Bioinformatics and Integrative Genomics Thesis Title The properties of natural selection on structural variation in the human genome Advisor Michael E. Talkowski, Ph.D. Dissertation Committee Shamil Sunyaev, Ph.D.; Mark Daly, Ph.D.; James Gusella, Ph.D.; Marcin Imielinski, M.D., Ph.D. A.B. Dartmouth College, Hanover, NH, USA 2009-2013 Department of
    [Show full text]
  • AC NEJM CH16 Release
    Media Contact : Kathryn Morris KMorrisPR 845-635-9828 [email protected] Research Published in New England Journal of Medicine Identifies New Chromosome Abnormality Strongly Associated with Autism Spectrum Disorders -- Autism Consortium Releases First Significant Findings from Scan of 3,000 Children and Families with Autism Spectrum Disorders -- BOSTON – JANUARY 09, 2007 – The Autism Consortium, an innovative research, clinical and family collaboration dedicated to radically accelerating research and enhancing clinical care for autism spectrum disorders (ASDs), reported strong and compelling evidence that a region on chromosome 16 appears to play an important role in susceptibility for ASDs. ASDs are diagnosed in as many as 1 in 150 children under the age of three. Symptoms can range from mild to severe and can include social, cognitive and behavioral deficits. The new findings, published online in advance of an upcoming issue of The New England Journal of Medicine (NEJM), are of particular significance because either a deletion or duplication of this section of chromosome 16 appears to contribute strongly to susceptibility to ASDs. In the majority of cases the deletion was de novo , a newly occurring change in the DNA that the affected individual did not directly inherit from either parent. The authors verified the clinical importance of their findings through independent observations in the Genetics Diagnostics Laboratory at Children’s Hospital Boston, a member of the Autism Consortium, and at deCODE Genetics Inc. in Iceland. The research team was led by Mark J. Daly, PhD, an Autism Consortium member at the Center for Human Genetic Research and the Department of Medicine at Massachusetts General Hospital; he is also a senior associate member of the Broad Institute of the Massachusetts Institute of Technology and Harvard.
    [Show full text]
  • PLINK Gplink Haploview Whole Genome Association Software Tutorial
    PLINK gPLINK Haploview Whole genome association software tutorial Shaun Purcell Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA Broad Institute of Harvard & MIT, Cambridge, MA http://pngu.mgh.harvard.edu/purcell/plink/ http://www.broad.mit.edu/mpg/haploview/ PLINK tutorial, December 2006; Shaun Purcell, [email protected] PLINK tutorial, December 2006; Shaun Purcell, [email protected] GUI for many PLINK analyses Data management Summary statistics Population stratification Association analysis IBD-based analysis PLINK tutorial, December 2006; Shaun Purcell, [email protected] Computational efficiency 350 individuals genotyped on 100,000 SNPs Load, filter and analyze ~12 seconds 1 permutation (all SNPs) ~1.6 seconds 5000 individuals genotyped on 500,000 SNPs Load PED file, ~68 minutes generate binary PED file Load and filter binary PED file ~11 minutes Basic association analysis ~5 minutes PLINK tutorial, December 2006; Shaun Purcell, [email protected] gPLINK / PLINK in “remote mode” Secure Shell networking Server, or cluster head node W W W gPLINK & Haploview: PLINK, WGAS data initiating and viewing jobs & computation PLINK tutorial, December 2006; Shaun Purcell, [email protected] AA simulatedsimulated WGASWGAS datasetdataset SummarySummary statisticsstatistics andand qualityquality controlcontrol WholeWhole genomegenome SNP-basedSNP-based associationassociation WholeWhole genomegenome haplotype-basedhaplotype-based associationassociation AssessmentAssessment ofof
    [Show full text]
  • Abstracts 2020
    Abstracts 2020 Abstract book sponsored by Talks Page Session 1 …………………………………………………2 Session 2 …………………………………………………3 Session 3 …………………………………………………6 Session 4 …………………………………………………9 Session 5 ………………………………………………..11 Session 6 ………………………………………………..15 Session 7 ………………………………………………..20 Session 8 ………………………………………………..23 Session 9 ………………………………………………..27 Session 10 ………………………………………………..33 Session 11 ………………………………………………..39 Session 12 ………………………………………………..43 Session 13 ………………………………………………..49 Session 14 ………………………………………………..53 Session 15 ………………………………………………..54 Session 16 ………………………………………………..58 Session 17 ………………………………………………..61 Session 18 ………………………………………………..64 Session 19 ………………………………………………..70 Session 20 ………………………………………………..76 Session 21 ……………………………………………… 80 Session 22 ………………………………………………..85 Session 23 ………………………………………………..88 Session 24 ……………………………………………… 91 Session 25 ………………………………………………. 94 Poster Presentations……………………………97-279 1 316 Quantitative Genetics Isn’t Dead Yet Professor Peter M. Visscher1 1Institute for Molecular Bioscience, University of Queensland, ST LUCIA, Australia Session 1, November 3, 2020, 7:00 AM - 8:30 AM Biography: Peter Visscher FRS is a quantitative geneticist with research interests focussed on a better understanding of genetic variation for complex traits in human populations, including quantitative traits and disease, and on systems genomics. The first half of his research career to date was predominantly in livestocK genetics (animal breeding is applied quantitative genetics), whereas the last 15 years he has contributed to methods,
    [Show full text]
  • Meeting Summary
    MEETING SUMMARY Grand Hotel Gullteigur Conference Room, Reykjavik, Iceland April 23-24, 2019 Hosted by the Global Genomic Medicine Collaborative (G2MC) Vision for success: A GLOBAL PLATFORM FOR TRANSLATIONAL RESEARCH (COHORT TO BEDSIDE AND COHORT TO BENCH), INFORMING BIOLOGICAL/GENETIC BASIS FOR DISEASE AND IMPACT ON CLINICAL CARE AND POPULATION HEALTH EXECUTIVE SUMMARY In 2015, the National Institutes of Health (NIH) launched an effort to identify all large-scale prospective cohort studies involving at least 100,000 (100K) participants to explore the potential of bringing them together to address scientific questions none could answer alone. The goal was, and remains, to create a global network for translational research that will utilize large cohorts to enhance understanding of the biological, environmental, and genetic basis of disease and to improve clinical care and population health. This effort was discussed at the June 2016 Heads of International Research Organizations (HIROs) meeting and reached an agreement to commission the Global Genomic Medicine Collaborative (G2MC), working with the Global Alliance for Genomics and Health (GA4GH), to bring the cohorts together for an initial summit, which was held in March 2018 in Durham, North Carolina. It involved 61 cohorts from 33 countries, representing current and expected cohort sizes of 30 million and 35 million individuals, respectively. Cohorts were invited based on four criteria: having 100K participants or more, were not selected for disease, having available biospecimens, and having at least the potential for longitudinal follow-up of participants. It soon became clear, however, that regions such as Africa, the Middle East, South America and South Asia were under-represented in such a compilation, so these criteria were relaxed somewhat to facilitate their participation.
    [Show full text]